Protagonist Therapeutics, Morgan Healthcare Conference

Digest more
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J...

Continue reading

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Joplin Globe · 1d
ME Therapeutics Attending JP Morgan Healthcare Conference
Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference
Artios Pharma Limited ("Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR”) in cancer, today announced that it will present ...

Continue reading

manilatimes · 13h
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
manilatimes · 13h
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
MMI to Present on Company Momentum and Innovation at 44th Annual J.P. Morgan Healthcare Conference
Mark Toland, Chief Executive Officer of MMI, will present on Monday, January 12 at 9:00 AM PT, at the Westin St. Francis Hotel, Mission Bay meeting room.

Continue reading

manilatimes · 1d
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
manilatimes · 1d
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
AZ Central

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that the company ...
Joplin Globe

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company ...
Pocono Record

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and ...
Feedback